Investigation Report on China Valsartan

ResearchMoz.us include new market research report" Investigation Report on China Valsartan " to its huge collection of research reports.

Valsartan (Angiotan or Diovan) is an angiotensin II receptor antagonist (more commonly called an ARB, or angiotensin receptor blocker), with particularly high affinity for the type I (AT1) angiotensin receptor.

View Full This Report With TOC @ http://www.researchmoz.us/investigation-report-on-china-valsartan-report.html

In December 1996, Valsartan was approved by FDA. In the US, UK and Australia, valsartan is marketed by Novartis under the trade name Diovan. In 1998, Valsartan was registered by Novartis in China with "Daiwen" as its brand name.

After Valsartan, Novartis developed Valsartan compound preparation. In October 1997, valsartan/hydrochlorothiazide was approved by FDA with "CoDiovan" as its brand name; New developed amlodipine/valsartan (Exforge) was also approved to the market.

There are many enterprises producing APIs and finished products of Valsartan. The market share of finished products is mainly occupied by Novartis, which is above 85% by sales value every year.

In China, the number of hypertensive patients has exceeded 200 million so the market prospect of Valsartan is bright.

List of Figures:

Chart Valsartan Products Approved to Market in China, 2014

Chart Forecast on Market Size of Hospital-use Valsartan in China, 2014-2018

Chart Sales Value of Valsartan in Global Market, 2009-2013

Chart Sales Value of Valsartan in Hospital Market in China, 2009-2013

Chart Sales Value of Valsartan by Region in China, 2009-2013

Chart Market Share of Valsartan Enterprises by Sales Value in China, 2009-2013

Chart Hospital Price of Valsartan Produced by Tianda Group

Chart Hospital Price of Valsartan Produced by Beijing Novartis

Browse All Latest Report Related to Pharmaceutical Research @ http://www.researchmoz.us/pharmaceutical-market-reports-38.html

About Us:

ResearchMoz is the one stop...